AC Immune (ACIU) to Release Quarterly Earnings on Monday

AC Immune (NASDAQ:ACIU) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect AC Immune to post earnings of ($0.22) per share and revenue of $0.32 million for the quarter.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $1.12 million for the quarter, compared to analysts’ expectations of $1.99 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Stock Up 0.6 %

AC Immune stock opened at $1.67 on Friday. The firm has a market cap of $167.68 million, a P/E ratio of -3.63 and a beta of 1.62. The business has a fifty day moving average of $1.84 and a two-hundred day moving average of $2.51. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.98.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. HC Wainwright dropped their price objective on AC Immune from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a report on Monday, May 5th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.